You are leaving Relmada.com
By clicking YES, you will be directed to another website. Click NO to remain on this page. Do you wish to continue to another website?
Our most advanced program is REL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels associated with major depressive disorder (MDD), while maintaining physiological glutamatergic neurotransmission. We believe that REL-1017 has the potential to transform the current neuropharmacological approach to MDD, and we are rapidly advancing toward investigating REL-1017 for potential indications as adjunctive and monotherapy.
Based on our Phase 1 and Phase 2 studies, we believe there is a real potential for REL-1017 to treat MDD safely, effectively, and more quickly than is currently possible with a well-tolerated, oral, once-daily tablet. REL-1017 received Fast Track Designation and has entered the pivotal Phase 3 programs with studies as an adjunctive treatment in adults. REL-1017 has also initiated a Phase 3 study for monotherapy.
We are growing our company accordingly as we execute our Phase 3 program: Reliance I, Reliance II, Reliance III, and Reliance-OLS for REL-1017. We have assembled an experienced development team to advance this promising program.
1) World Health Organization https://www.who.int/news-room/fact-sheets/detail/depression.